Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study.
Saved in:
| Title: | Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study. |
|---|---|
| Authors: | Lin, Min‐Hsi1,2 (AUTHOR), Chu, Kuo‐An1,3 (AUTHOR), Chen, Chiu‐Fan1 (AUTHOR), Jiang, You‐Cheng1 (AUTHOR), Hong, Wei‐Cheng1 (AUTHOR), Hung, Ming‐Yen1 (AUTHOR), Hsu, Chun‐Hsiang1,4 (AUTHOR) benhsu740124@gmail.com |
| Source: | Cancer Medicine. May2026, Vol. 15 Issue 5, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20457634 |
|---|---|
| DOI: | 10.1002/cam4.71881 |
